Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

The oncologist - 1 Jan 2013

Gainor Justin F, Shaw Alice T

Abstract excerpt

The discovery of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) has stimulated renewed interest in oncogenic fusions as potential therapeutic targets. Recently, genetic alterations in ROS1 and RET were identified in patients with NSCLC. Like ALK, genetic alterations in ROS1 and RET involve chromosomal rearrangements that result in the formation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to In Situ Hybridization, Fluorescence
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-ret

Share to Translocation, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 23814043
DOI: 10.1634/theoncologist.2013-0095
PMCID: PMC3720641

Genes

RET
ROS1
ALK
EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.PMID 23814043Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.Semantic proximity Read ↗

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.Semantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Progress of non-small-cell lung cancer with ROS1 rearrangementSemantic proximity Read ↗

[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].Semantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

RET-rearranged non-small-cell lung cancer and therapeutic implications.Semantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

New Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.